Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alpine Transformations Fund Institutional Class (ADTRX)

15.53
Net Asset Value
+0.52%
1 Day
+6.74%
Year-to-Date
Overall Morningstar Rating
Mid-cap growth
Style or Category
No Load
Sales Expenses
1.89%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. The fund seeks to invest in equity securities of companies that, in the Adviser's estimation, are entering or on the verge of entering an accelerated growth period catalyzed by transformation. The Adviser seeks to identify investment opportunities in securities of companies that it believes are undervalued in light of the companies' potential for vigorous growth. The fund is not restricted on how much may be invested issuers of a single country, provided that it limits its investment in countries that are considered "emerging markets" to no more than 35% of its net assets.

Performance

1 month+1.24% 3 years+17.01%
3 months+3.40% 5 years+14.75%
1 year+11.61% Since inception+8.67%
Data through --

Peer Comparisonvs. Mid-cap growth

 ADTRXCategory
Performance 5-yr return+14.75%+16.81%
Expense ratio1.89%1.32%
Risk 5 year sharpe ratio1.001.12
Net assets$8.4M$1.4B
Average market cap$7.5B$9.6B
Average P/E22.725.9
Portfolio turnover50%50%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyAlpine
Fund manager & tenureStephen Lieber / 7 Years
Minimal initial investment$1,000,000.00
Minimum IRA investment$1,000,000.00

Holdings

U.S. stock79.63%
International stock10.96%
Cash9.41%
Fixed income0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 23.42%
Industrial materials 21.75%
Business service 9.20%
Financial service 9.11%
Consumer service 9.07%
Top 10 Holdings
Portfolio weighting
SNA Snap-On Inc4.68%
PCLN Priceline3.87%
DLX Deluxe Corp3.38%
EW Edwards Lifesciences Corp2.64%
JAH Jarden Corp2.40%
MNK Mallinckrodt Plc2.36%
UHAL Amerco2.35%
RCPT Receptos Inc2.31%
-- 2.30%
CRAY Cray Inc2.27%